# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Anupam Rama downgrades Rallybio (NASDAQ:RLYB) from Overweight to Neutral.
-SEC Filing
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:RLYB) with a Buy and maintains $9 price target.
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.50) by 6...
JMP Securities analyst Jonathan Wolleben reiterates Rallybio (NASDAQ:RLYB) with a Market Outperform and maintains $8 price t...
JMP Securities analyst Jonathan Wolleben reiterates Rallybio (NASDAQ:RLYB) with a Market Outperform and maintains $8 price t...
- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women -- Among HPA-1a Negative Pr...
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.